#1SARTORIUS Simplifying Progress Investors Presentation April 2024#2Sartorius Group Agenda Overview | Strategy Bioprocess Solutions Division Lab Products & Services Division Q1 2024 Results | FY 2024 Guidance 2 SARTORIUS#3Sartorius Group Partner of Life Science research and the biopharmaceutical industry 3 3 GOOD HEALTH AND WELL-BEING Good health and well-being at the focus of Sartorius' business activities SUSTAINABLE DEVELOPMENT GOALS SARTORIU Our mission We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine. SARTORIUS#4Sartorius Group Sartorius at a glance € ~€3.40bn Sales revenue 2023 ~15% Sales CAGR¹ 2013-2023 Two divisions focused on attractive biopharma and life science markets G 28.3% EBITDA margin2 2023 60+ Пи Locations worldwide, HQ in Göttingen, Germany ~14,600 Employees 12/2023 1 In constant currencies 2 Excluding extraordinary items 4 Sales 2023 79% 21% Bioprocess Solutions Division ~€3.40bn Lab Products & Services Division ~85% with life science customers SARTORIUS#5Sartorius Group Products and solutions span from lab to production. 5 Bioprocess Solutions Division Molecule development Cell line and process development Quality | Testing | Validation. Upstream & downstream production пос Lab Products & Services Division SARTORIUS#6Sartorius Group Attractive market environment offers strong growth opportunities Growing and aging population >9.5 billion people by 20501 Biologics are gaining importance² World population over age 65 in 2050 ~1.6bn Sales share of biologics in 2028 ~44% World population over 65 in 2022 ~0.8bn Sales share of biologics in 2023 -39% ~10% CAGR biopharma market 2023 2028 1 United Nations: World Population Prospects, 2022 2 Evaluate Pharma: World Preview 2023, August 2023 3 Company estimates based on industry reports (e.g. IQVIA, Evaluate Pharma, globaldata etc.), 2023 6 SARTORIUS#7Sartorius Group Strong track record of profitable growth. Sales CAGR 2013-19 ~14% Sales CAGR 2019-23 ~17% ~€3.40bn ~€1.83bn 34.1 33.8 29.6 28.3 ~€790m 25.0 25.1 25.9 27.1 23.6 20.5 21.0 2013 2014 2015 Sales revenue EBITDA¹ margin in % 2016 2017 2018 2019 2020 2021 2022 2023 Intec Division; divested in 2|2015 Sales CAGR for continued operations, in constant currencies; EBITDA margin excluding extraordinary items 7 SARTORIUS#8Sartorius Group Fueling organic growth; improved resilience by robust regional set-ups. 8 Capex in millions of €; ratio in % 560 Capex composition Global Resilience Redundant Capacity Customer proximity Operational Excellence 16,5 Major projects ~X% ~13 Regular expansion ~3% Capitalized R&D ~2% Maintenance ~3% 2023 2024e Ann Arbor, Michigan, USA Bioanalytics products & services completion in 2024 Songdo, South Korea Cell culture media, bags, filtration, laboratories, training completion by end of 2025 SARTORIUS#9Sartorius Group Expansion projects proceeding according to plan Göttingen, Germany Bioanalytics products and services Product development, membrane production, filtration Ann Arbor, Michigan, USA ..SARTORIUS SART Yauco, Puerto Rico, USA Cell culture media, bags, filtration Aubagne, France Clean rooms, product development, laboratories, offices, storage HOME ER Songdo, South Kora Cell culture media, bags, filtration, laboratories, training Peking, China Bags SARTORIUS#10Sartorius Group M&A strategy - adding innovation, enhancing focus Essen BioScience Life Science assets from Danaher 2017 2019 2020 Umetrics Biological Industries Acquisition criteria 10 10 ALS 2021 2022 2023 xell BIA Separations WaterSep CellGenix Xell Chrom. assets from Novasep Albumedix Portfolio: Complementary products or technologies Market position: Either among the Top 3 or unique selling point Integration: Management capacity; cultural fit Price: Fair valuation; reach Sartorius' profitability level in 2-3 years Polyplus Polyplus SARTORIUS#11Sartorius Group Polyplus acquisition a milestone for creating a technology platform for applications in the CGT market 11 Biological Industries CellGenix Xell Albumedix Polyplus xell xell xell Albumedix ΔΑΠ AAN Cell culture media Growth factors and cytokines Media and supplements Recombinant Albumin Polyolus + Up & downstream solutions Transfection reagents and plasmid DNA Cell line development, plasmid design & manufacturing, testing services Polyplus spec'd into significant portion of approved & pipeline CGT Sartorius CGT exposure >10% of BPS sales revenue | ~ CAGR 2019-23: >35% SARTORIUS#12Sartorius Group Cell and gene therapies (CGT) an increasingly relevant market segment ~30% of biopharma pipeline is focusing on CGT1 ~70% Other biologics -30% CGT Number of commercial processes is expanding rapidly ~60 approved CGT globally¹ 11 CGT approvals in 2022 and 2023 alone >6,000 CGT candidates in development¹ ■ 7 new CGT (2022: 5) approvals in 2023 out of 42 BLA approvals in total (2022: 31) 2 10-20 CGT approvals expected p.a. by 20252 1 GlobalData, October 2023 2 FDA, includes CDER and CBER approvals 12 SARTORIUS#13Sartorius Group Broad set of ambitious sustainability targets 2030 mid-term targets ~ 10% av. reduction of CO2eq emission intensity p.a. (Scopes 1-3) Zero avoidable¹ emissions in Scopes 1 and 2 100% electricity from renewable sources >75% revenue with products designed according to circularity principles Zero disposal of operational waste to landfill 35 av. annual Employee Net Promoter Score 2045 long-term target Net-zero emissions Decarbonization of the entire supply chain in collaboration with suppliers and customers 1 Process emissions from membrane manufacturing are currently considered unavoidable based on available technology, 2 Including product and transport packaging 13 SARTORIUS#14Sartorius Group Midterm outlook to 2028: Expect to continue outgrowing the market BPS LPS Sartorius Group Sales revenue CAGR to 2028 Underlying EBITDA margin in 2028 Low to mid- teens % Mid to high single-digit % Low-teens % ~36% ~28% ~34% ◉ ~1/5 of sales revenue growth to come from acquisitions in both divisions and the Group Margin targets include expenses for reduction of the company's CO2 emission intensity of around 1% of sales Midterm targets based on current currency exchange rates; underlying EBITDA excluding extraordinary items 14 SARTORIUS#15Sartorius Group Agenda SIRTSPILS Overview | Strategy Bioprocess Solutions Division Lab Products & Services Division Q1 2024 Results | FY 2024 Guidance + 15 TIP BOX LIDS SARTORIUS Cell Culture Media Media Sample S TE LIDS 11 Oden XXXXXX La number 100K We 000 Ma de 042000 2-80 For Further Laboratory Use Gre SARTORIUS#16Sartorius Group Bioprocess Solutions (BPS): solution provider for biomanufacturing € ~€2.68bn Sales revenue 2023 ☺ 29.2% EBITDA margin ¹ 2023 ~75% Recurring revenues ~90% Sales share biopharma 1 Excluding extraordinary items 16 16 M Filtration SARTORIUS SPRE Purification Fermentation Fluid management SARTORIUS#17Sartorius Group Track record of dynamic growth; balanced regional revenue profile BPS sales revenue; EBITDA margin¹ in % CAGR² 18% ~€1.14bn 28.6 ~€2.68bn Pillars of growth CAGRS 2022-20271 Pharma market -3-6% Biopharma market -10% Y Biosimilars -15% 핫 CGT -20% 29.2 2018 Sales revenue 2019 2020 2021 2022 2023 EBITDA¹ margin in % 1 Excluding extraordinary items 2 In constant currencies 17 Single-use ~15% SARTORIUS#18Sartorius Group Generating revenue throughout the lifecycle of a biopharma drug Stage Preclinical (1 year) Scale Process development Clinical (4-7 years) Commercial (15+ years) Proof of concept - pilot Large ■ Wide product range of equipment and consumables for all stages (from pre-commercial to large-scale manufacturing); optimal scalability Engineering support with excellent application knowhow and understanding of the entire bio-production process Production process of each individual drug is subject to validation by health authorities (e.g. FDA, EMA) and part of the drug approval 18 SARTORIUS#19Sartorius Group Covering most steps of the biopharmaceutical manufacturing process. ■ Differentiated by the range and completeness of the portfolio ☐ ■ Excellent positioning in key single-use technologies ■ Internationally recognized. supplier enabling innovation in bioprocessing through own R&D and partnerships 19 Culture media preparation Seed cultivation UPSTREAM Scale-up Production DOWNSTREAM Final Cryo- Sterile filling preservation filtration Concen- tration Virus clearance & filtration Chroma- tography Clarification & centrifugation SARTORIUS#20Sartorius Group Integrated services and technologies for all types of biopharmaceuticals Vaccines 20 20 mAbs Regenerative medicine Engineered tissue Bioconjugates ■ ~95% of BPS revenue generated with bio/pharma customers ■ Solutions for the production of all biotechnologically derived drugs and cell derivatives ■ Antibodies are most relevant; strong position in vaccines as well New modalities such as cell and gene therapies and viral vectors with increasing relevance SARTORIUS#21Sartorius Group Competitive product offering 0° 222 21 21 Σ Filtration Fluid Management Fermentation 이 A ΔΙ 闘 Purification Sartorius Merck | Millipore Danaher Thermo Fisher Cell Culture Media Top 3 Players All player with approx. equal market shares 1. Sartorius 2. Thermo Fisher 3. Merck | Millipore 1. Sartorius 2. Thermo Fisher 3. Danaher | Cytiva 1. Danaher | Cytiva 2. Merck | Millipore 3. Sartorius 1. Thermo Fisher 2. Merck | Millipore 3. Danaher | Cytiva Pie charts indicate completeness of product offering SARTORIUS#22Sartorius Group Biosimilars: Strong growth, big opportunities ☐ Major blockbuster biologics are going off-patent Time-to-market is key as only the first providers are most likely profitable Several approvals in Asia and Europe; U.S. at the beginning ■ For now, relatively small market but with strong growth Single-use is the preferred platform for biosimilars Biosimilars will outperform the biologics market¹ 2023 ~15% CAGR 2028 Growing number of approved biosimilars² E.U. and U.S. Biosimilars Other biologics 0 1 Source: MarketsandMarkets, 2023; Evaluate Pharma, 2023 2 FDA and EMA 22 22 7 22 20 15 16 16 13 10 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 SARTORIUS#23Sartorius Group Pioneer and leader in the growing single-use technology market Single-use market penetration expected to increase from ~35% to ~75% Single-use products offer advantages over conventional stainless-steel devices Capex Opex reduction over entire lifecycle ■ Reduced risk of cross-contamination ☐ ■ Higher flexibility; advantageous for biosimilars Reference Single-use -65-75% -25-35% -30-50% IELL -55-65% Construction cost Time-to-market Energy cost Water cost Source: Andrew Sinclair et al., 2008; Sartorius 23 333 SARTORIUS#24Sartorius Group Single-use allows manufacturers to mitigate investment risks ◉ Construction of stainless-steel based facilities takes longer and is more complex compared to single-use Therefore, investment in stainless-steel facilities has to start in early clinical phase II ■ The construction of single-use facilities may start in clinical phase III, reducing investment risks of clients Probability that candidate advances to next stage Clinical Phase | Clinical Phase || Clinical Phase III ~ 60% 2 ~ 30% ~ 50% Probability of approval 2 - 10% ~ 15% ~ 50% Data based on: Wong et al., 2018 24 SARTORIUS#25Sartorius Group Analytical technologies to improve process economics and safety BPAI MICS 25 E 18 101010 Bioprocess sensors, analyzers and software ◉ Collect, monitor and control quality-critical parameters Analyze data to obtain a better process understanding. Use knowledge for process development, optimization and automation ■ Allows customers to increase time-to-market, to reduce COGS, to improve process robustness and product quality Intention to upgrade Umetrics software suite with advanced analytics technologies such as Al and machine learning Data analytics just at the beginning in biomanufacturing with high potential SARTORIUS#2626 Sartorius Group High innovation dynamics in Biopharmal 888 昌 Development of new drugs and vaccines must be accelerated, e.g. through more automation Increased efficiency possible in the production of 'classic' biopharmaceuticals and biosimilars New tools and methods required e.g. for novel cell and gene therapies Future drug manufacturing is more automated, intensified and scalable SARTORIUS#27Sartorius Group Limited dependence on individual accounts Long-term business relationships with leading global (bio-) pharma companies Limited dependence on individual accounts Sales to Top 50 customers in 2023, € in millions gsk GlaxoSmithKline SAMSUNG BIOLOGICS Boehringer Ingelheim 800 ~57 600 ~52 ~47 Lonza Roche Pfizer ~39 400 ~26 SANOFI 200 AMGEN 0 REGENERON More than half of 2023 BPS sales were generated with the Top 50 customers MSD Top 10 11 to 20 21 to 30 31 to 40 41 to 50 Sales Cumulative Share ☐ 27 No individual customer accounts for more than 5% of BPS sales revenue SARTORIUS#28Sartorius Group Agenda Overview | Strategy Bioprocess Solutions Division Lab Products & Services Division Q1 2024 Results | FY 2024 Guidance 28 BROO 865488 DECRY SARTORIUS OCTET RB SARTORIUS#29Sartorius Group Lab Products & Services (LPS): premium supplier for Life Science research and quality control labs € ☺ ~€720mn Sales revenue 2023 25.1% EBITDA margin2 2023 45% Recurring revenue ✓ ~60% Sales share Life Sciences Portfolio includes lab instruments, consumables, software and services SARTORIUS NOUCHE SAR Bioanalytics Lab instruments 1 In constant currencies 2 Excluding extraordinary items 29 Lab consumables SARTORIUS#30Sartorius Group Continuous transition to a higher growth and profitability profile LPS sales revenue; EBITDA margin¹ in % ~€423m 18.5 2018 CAGR² 11% ~€718m 25.1 2019 2020 2021 2022 2023 EBITDA¹ margin in % Sales revenue 1 Excluding extraordinary items 2 In constant currencies 30 30 Growth drivers Sales & Marketing pivot to attractive segments and regions Attractive portfolio mix coupled with M&A Launch of innovative products Q Improved brand awareness SARTORIUS#31Sartorius Group Focus on attractive Life Science market; regional profile increasingly balanced Sales revenue share by segment, 2023 vs. 2018 Sales revenue share by geography, 2023 vs. 2018 31 Life Science research ~60% (~43%) of which Bioanalytics >35pp (~17pp) 2023 Applied 2023 research ~40% (~57%) Americas ~32% (~26%) EMEA ~38% (~46%) 2018 2018 Asia | Pacific ~30% (~28%) SARTORIUS#3232 32 Sartorius Group Strong market position in essential laboratory product categories ■ Average global market share of >10% High gross margins offer potential for economies of scale ■ Growth potential especially in the U.S. and Asia ■ Market growth related to R&D ☐ spending in the individual end markets MITURIA ** 1006441. SARTORIUS Lab balances Microb. analysis Lab filtration #2 #2 #3 Pipettes #4 SARTORIUS 120.0 Ficus 120 NORIS#33Sartorius Group Bioanalytical tools to address pain points of our customers Drug discovery Preclinical testing Clinical trials Drug approval 4-5 years 1 year 4-7 years 1-2 years >10 years ~10% >€2bn Probability of clinical success (Phase I to approval) From drug discovery to approval Average costs of developing a successful drug Based on data from the Tufts Center for the Study of Drug Development and the Association of the British Pharmaceutical Industry 33 Our approach ■Facilitate digitalization and automatization ■ Decrease likelihood of failure ■ Reduce time and costs in molecule development; increase speed-to-market SARTORIUS#34Sartorius Group Overview of bioanalytical portfolio 34 =4 Solutions for cell analysis IncuCyte: Real-time imaging and analysis of living cells ¡Que Screener: Rapid, high content analysis of cells, beads and secreted proteins Competitive environment ☐ Beckman Coulter ■ Becton Dickinson ■ Bio-Rad ■ Cytival ■ Merck ■ PerkinElmer ☐ Thermo Fisher Solutions for protein analysis ■ Octet: Real-time, label-free measurement of biomolecular interactions SARTORIUS#35Sartorius Group Solutions complement each other, optimize successive workflows and have synergies with BPS products Application example: Molecule development B iQueScreener Screening of antibody libraries for target-reactive candidates Application example: Cell line development Octet Identify high-producing clones in expression library 35 A Octet Measure how strong the identified antibodies bind to their target and rank ambr15 (BPS division) Culture identified clones on small-scale STERILS IncuCyte | iQueScreener Selection of lead candidates and functional characterization Octet | iQueScreener Analysis and characterization of cell line and antibodies SARTORIUS#36Sartorius Group Total addressable market increased since 2018 Total addressable market of LPS 36 2023 ~€7.9bn 2018 ~€3.6bn ■ Market opportunity increased through expanded product offering (e.g., addition of Octet and CellSelector platforms, specialty media, GMP cytokines and OEM diagnostic membranes) ■ Higher exposure to faster growing segments in Life Science ■ Overall addressable market growing in the mid- to high- single digits SARTORIUS#37Sartorius Group Agenda Overview | Strategy Bioprocess Solutions Division Lab Products & Services Division Q1 2024 Results | FY 2024 Guidance 37 SARTORIUS#38Sartorius Group Expected soft top line development vs. strong PY; robust profitability Sartorius Group Q1 2023 Q1 2024 in % ▲ in % cc1 in millions of € unless otherwise specified Sales revenue 903 820 -9.3 -7.6 Order intake 765 826 8.0 9.8 Underlying EBITDA² 272 234 -13.8 Underlying EBITDA² margin in % 30.1 28.6 -1.5pp Underlying EPS³ (ord.) in € 1.69 1.01 -40.5 Underlying EPS³ (pref.) in € 1.70 1.02 -40.3 ☐ Sales down on strong comps; acquisitions contribute ~2pp to sales growth ■ Ol: noticeable pick-up in recurring business indicate advanced inventory reductions of customers; weak equipment business mainly in China and partly in Europe ■ Underlying EBITDA margin on robust level; efficiency programs contribute positively 1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate 38 SARTORIUS#39Sartorius Group Demand normalization in all regions except China Americas EMEA Sales | € in millions Sales | € in millions -9.3% -4.4% 359 322 288 Asia | Pacific Sales | € in millions Sales by region in % -10.4% EMEA ~42% 341 222 190 €820m Americas ~35% Asia | Pacific ~23% Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024 ☐ Americas: Strong Ol development in both divisions (BPS: ~+30%; LPS ~+14%); lower revenue on strong comps ◉ EMEA: Positive Ol development in BPS (~+8%), flat in LPS; sales down on strong comps; Russia impact on top line --1pp ■ Asia | Pacific: Ol in BPS up (~+7%), while down in LPS (~-29%); sales down in both divisions; China weighing on APAC sales growth with -12pp; Korea and rest of region show positive sales development Acc. to customers' location; growth in constant currencies 39 SARTORIUS#40Sartorius Group Bioprocess Solutions: Recurring business continues to recover while equipment remains soft Order intake € in millions Sales revenue Underlying EBITDA & margin € in millions € in millions 15.0% cc -5.3% cc 13.4% -6.9% -11.1% 695 653 576 647 217 193 SARTORIUS Q1 2023 Q1 2024 ■ M&A contributes ~3pp to sales development ◉ Q1 2023 Q1 2024 31,2 29,8 Q1 2023 Q1 2024 Ol growth in all regions, however China down; continuous recovery of recurring business also vs. relatively positive Q4 2023; muted investment activity dampens equipment business ■ UI. EBITDA margin on robust level; lower volumes partly compensated by positive product mix effects and cost base adjustments 40 40#41Sartorius Group Lab Products & Services: Below strong Q1 2023 but recovery ongoing except for China; investment activity widely soft Order intake € in millions -6.2% cc -8.2% 189 173 Sales revenue Underlying EBITDA & margin € in millions € in millions -15.3% cc -17.1% 208 173 -24.4% 55 41 26,3 24,0 Q1 2023 Q1 2024 Q1 2023 Q1 2024 Q1 2023 Q1 2024 ■ Ol below Q1 2023 but above Q4 2023; strong recurring business; particularly dynamic development in Americas Sales revenue below strong Q1 2023 but above Q3 and Q4 2023 Underlying EBITDA margin impacted by lower volumes and product mix. 11 41 SARTORIUS#42Sartorius Group Operating cash flow influenced by phasing effects Sartorius Group in millions of € unless otherwise specified Underlying EBITDA 272 234 -13.8 Extraordinary items -19 -16 +14.7 Financial result -12 -49 >-100 Underlying net profit 1,2 116 70 -39.9 ■ Reported net profit² 93 37 -60.6 Operating cash flow 202 45 -77.6 Q12023 Q1 2024 ▲ in % Extraordinary items driven by reorganization and integration measures and corporate projects ■ Financial result influenced by higher interest expenses Operating cash flow below PY due to phasing effects of tax payments, lower factoring volume and lower earnings Capex ratio elevated on lower sales revenue Investing cash flow³ Capex ratio (in %) -137 -135 +1.5 15.0 15.7 +0.7pp SARTORIUS 1 Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and a normalized tax rate 2 After non-controlling interest 3 Net cash flow from investing activities and acquisitions 42 42#43Sartorius Group Balance sheet reflects recent capital measures; focus on strong cash generation to drive further deleveraging Key financial indicators Net debt and net debt to underlying EBITDA Sartorius Group in millions of € unless otherwise specified Dec. 31, 2023 Mar. 31, 2024 5.000 Non-current assets 7,798 7,849 4.000 3.000 Equity ratio in % 28.3 35.4 2.000 NWA UO 6,0 5,0 4,0 3,0 2,0 Net debt 4,932 4,097 1.000 1,0 0 0,0 Q1-Q4 Net debt | underlying EBITDA¹ 5.0 4.4 2020 Q1-Q4 2021 Q1-Q4 2022 Q1-Q4 Q1 FYe 2023 2024 Net debt in millions of € (lhs) Net debt to underlying EBITDA (rhs) 1 Includes underlying pro forma EBITDA of acquisitions completed in the last 12 months 23 43 SARTORIUS#44Sartorius Group Guidance 2024 confirmed: Profitable growth with moderate H1 2024 Guidance 20241 Sartorius Group thereof from acquisitions Bioprocess Solutions thereof from acquisitions Sales revenue growth Mid-to high single-digit percentage range ~1.5 pp Mid- to high single-digit percentage range ~2 pp Underlying EBITDA margin slightly above 30% above 31% Lab Products & Services Low single-digit percentage range ■ Growth momentum projected to pick up in the course of the year; H2 stronger than H1 ■ Polyplus business to positively influence BPS margin Capex ratio expected at -13% approx. on prior year level (2023: 25.1%) ■ Net debt to underlying EBITDA anticipated to be slightly above 3 at year-end (excl. possible equity measures and/or acquisitions) 44 1 In constant currency SARTORIUS#45Sartorius Group 45 45 Appendix SARTORIUS#46Sartorius Group Corporate responsibility & further financial information To Sartorius, sustainability means operating responsibly over the long term - with respect to business partners, employees and society as well as to natural resources. Learn more about our commitment: SRI Presentation Please click below for further financial information: Earnings Release Q1 2024 Sustainability Report 2023 Earnings Release FY 2023 Annual Report FY 2023 SATUR Earnings Release 9M 2023 46 446 SARTORIUS#47Sartorius Group Reasons to invest Biopharma market fueled by long-term growth drivers 213 Leading market positions; mission-critical portfolio; high brand awareness Global presence 平 High entry barriers; low price- sensitivity and consolidated High share of recurring revenues Ambitious ESG agenda competitive landscape 1 In constant currencies 47 SARTORIUS#48Sartorius Group Sartorius legal & operational structure Sartorius AG (~69.0m shares) Stock market listed in Germany¹ Sartorius Group legal setup Ordinary shares (~34.2m shares) ~55% Administered by executor ~38% Bio-Rad Laboratories ~7% Free float Preference shares (~34.8m shares) ~72% Free float ~28% Bio-Rad Laboratories ~71.5% 97.3m shares ~71.5% Sartorius AG ~28.5% Free float Sartorius Stedim Biotech S.A. Stock market listed in France 100% Other Sartorius subsidiaries Bioprocess Solutions division Lab Products & Services division Sartorius Group operational setup 1 The ownership relates to outstanding shares and thus excludes treasury shares. Information on shareholdings and shares in free float pursuant to the disclosure requirements of Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders' own disclosures. The legal disclosure requirements refer only to voting shares and not to non-voting preference shares. 48 SARTORIUS#4940 49 0% Jan. 20 100% 200% Apr. 20 300% Jul. 20 400% Okt. 20 500% Sartorius Group Share price performance 60 Jan. 21 Sartorius preference share Apr. 21 Jul. 21 Okt. 21 - Sartorius ordinary share Sartorius Stedim Biotech Jan. 22 Apr. 22 ISIN Ticker DE0007165631 (preference share) DE0007165607 (ordinary share) SRT3 (preference share) | SRT (ordinary share) Number of 69,035,489 - thereof pref. shares: 34,803,080 shares (excluding ~2.6m treasury shares); ord. shares: 34,226,009 (excluding ~3.2m treasury shares) Indices DAX 50 ESG | DAX | TecDAX | MSCI Europe CDAX | Prime All Share Index | Technology All Share Index | STOXX Europe 600 Market cap. €20.0bn (as of April 17, 2024) Jul. 22 DAX Okt. 22 -TecDAX Jan. 23 SARTORIUS Apr. 23 MSCI Europe Jul. 23 Okt. 23 Jan. 24 Apr. 24#50Sartorius Group A sampling of the Bioprocess Solutions' product portfolio M 50 50 Filtration Fermentation SABLE Purification SUCES 30 Fluid management SARTORIUS SARTORIUS#51Sartorius Group A sampling of the Lab Products and Services' product portfolio 51 MORE 0.00 Lab balances | Lab water systems Bioanalytics SARTOLAB Sorre Lab filtration | Microb. analysis Pipettes SARICALS SPRTORIUS SARTORIUS#52529 52 Sartorius Group Executive Board of Sartorius AG Joachim Kreuzburg, CEO Joined Sartorius in 1999 Member of the Board since 2002 Group Strategy, Corp Research, HR, Legal & Compliance, Communications, Sustainability René Fáber Joined Sartorius in 2002 Member of the Board since 2019 Bioprocess Solutions Division Florian Funck, CFO Joined Sartorius in 2024 Member of the Board since April 1, 2024 Finance, Information Technology, Data Management, Corporate Sourcing Alexandra Gatzemeyer Joined Sartorius in 2005 Member of the Board since May 1, 2023 Lab Products & Services Division SARTORIUS#53Sartorius Group Contacts and Financial calendar Petra Kirchhoff Head of Corporate Communications & IR +49.551.308.1686 [email protected] Petra Müller Head of Investor Relations +49.551.308.6035 [email protected] Mirko Koch Manager Investor Relations +49.551.308.2402 [email protected] Sartorius Corporate Administration GmbH Otto-Brenner-Straße 20 37079 Göttingen, Germany ◉ ◉ ◉ May 16, 2024 Capital Markets Day | Göttingen May 30, 2024 Kepler Cheuvreux ESG Conference | Virtual June 19, 2024 Citi's European Healthcare Conference June 20, 2024 JP Morgan European Healthcare Forum July 19, 2024 Publication Half-Year Report 2024 September 05, 2024 Morgan Stanley Global HC Conference October 17, 2024 Publication 9M 2024 Results 53 33 SARTORIUS#54549 54 Sartorius Group Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this presentation, differences may be apparent as a result of rounding during addition. SARTORIUS#55Scan or click here to visit our IR website. SARTORIUS